Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s share price was down 1.7% on Thursday . The company traded as low as C$2.60 and last traded at C$2.60. Approximately 6,138 shares traded hands during trading, a decline of 17% from the average daily volume of 7,410 shares. The stock had previously closed at C$2.65.
Eupraxia Pharmaceuticals Trading Down 1.7 %
The business’s 50-day moving average is C$2.80 and its two-hundred day moving average is C$3.65.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- What is a SEC Filing?
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- Do ETFs Pay Dividends? What You Need to Know
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.